Abiopharma

uniQure NV (QURE) Announces Clinical Trial Update uniQure NV (QURE) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: adults, option
• Diseases/Conditions: hemophilia, etranacogene dezaparvovec
• Clinical Stage: Phase III, pivotal study
• Collaboration: the Biologics License Application
  • anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with the impact of the ongoing COVID-19 pandemic on our Company and the wider economy and health care system, our Commercialization and License Agreement with CSL Behring, our clinical development activities, clinical results, collaboration arrangements, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company’s periodic securities filings, including its Annual Report on Form 10-K filed February 25, 2022